Adverum Biotechnologies Inc. [NASDAQ: ADVM] loss -16.63% or -3.11 points to close at $15.59 with a heavy trading volume of 2217965 shares.
It opened the trading session at $18.72, the shares rose to $18.72 and dropped to $15.56, the range by which the price of stock traded the whole day. The daily chart for ADVM points out that the company has recorded 8.60% gains over the past six months. However, it is still -214.31% lower than its most recent low trading price.
If we look at the average trading volume of 1.08M shares, ADVM reached to a volume of 2217965 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Adverum Biotechnologies Inc. [ADVM]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for ADVM shares is $25.75 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on ADVM stock is a recommendation set at 2.10. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Raymond James have made an estimate for Adverum Biotechnologies Inc. shares, keeping their opinion on the stock as Underperform, with their previous recommendation back on June 26, 2020. While these analysts kept the previous recommendation, RBC Capital Mkts raised their target price to Outperform. The new note on the price target was released on May 13, 2020, representing the official price target for Adverum Biotechnologies Inc. stock. Previously, the target price had yet another raise from $13 to $21, while SunTrust kept a Buy rating on ADVM stock.
The Average True Range (ATR) for Adverum Biotechnologies Inc. is set at 1.23, with the Price to Sales ratio for ADVM stock in the period of the last 12 months amounting to 4021.18. The Price to Book ratio for the last quarter was 3.78, with the Price to Cash per share for the same quarter was set at 3.84.
Trading performance analysis for ADVM stock
Adverum Biotechnologies Inc. [ADVM] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -11.62. With this latest performance, ADVM shares dropped by -14.72% in over the last four-week period, additionally plugging by 8.60% over the last 6 months – not to mention a rise of 35.80% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ADVM stock in for the last two-week period is set at 37.38, with the RSI for the last a single of trading hit 33.70, and the three-weeks RSI is set at 39.89 for Adverum Biotechnologies Inc. [ADVM]. The present Moving Average for the last 50 days of trading for this stock 20.20, while it was recorded at 17.75 for the last single week of trading, and 14.12 for the last 200 days.
Adverum Biotechnologies Inc. [ADVM]: A deeper dive into fundamental analysis
Operating Margin for any stock indicates how profitable investing would be, and Adverum Biotechnologies Inc. [ADVM] shares currently have an operating margin of -27418.00. Adverum Biotechnologies Inc.’s Net Margin is presently recorded at -25794.40.
Return on Total Capital for ADVM is now -33.53, given the latest momentum, and Return on Invested Capital for the company is -31.87. Return on Equity for this stock declined to -34.29, with Return on Assets sitting at -29.57. When it comes to the capital structure of this company, Adverum Biotechnologies Inc. [ADVM] has a Total Debt to Total Equity ratio set at 18.55. Additionally, ADVM Total Debt to Total Capital is recorded at 15.64, with Total Debt to Total Assets ending up at 14.57. Long-Term Debt to Equity for the company is recorded at 16.18, with the Long-Term Debt to Total Capital now at 13.65.
Reflecting on the efficiency of the workforce at the company, Adverum Biotechnologies Inc. [ADVM] managed to generate an average of -$565,667 per employee.Adverum Biotechnologies Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 17.90 and a Current Ratio set at 17.90.
Adverum Biotechnologies Inc. [ADVM]: An earnings per share (EPS) analysis
With the latest financial reports released by the company, Adverum Biotechnologies Inc. posted -0.25/share EPS, while the average EPS was predicted by analysts to be reported at -0.26/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 3.80%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for ADVM.
An analysis of insider ownership at Adverum Biotechnologies Inc. [ADVM]
There are presently around $1,322 million, or 80.01% of ADVM stock, in the hands of institutional investors. The top three institutional holders of ADVM stocks are: RA CAPITAL MANAGEMENT, L.P. with ownership of 7,272,714, which is approximately New of the company’s market cap and around 0.50% of the total institutional ownership; AVORO CAPITAL ADVISORS LLC, holding 7,150,000 shares of the stock with an approximate value of $111.47 million in ADVM stocks shares; and VERSANT VENTURE MANAGEMENT, LLC, currently with $109.19 million in ADVM stock with ownership of nearly -0.91% of the company’s market capitalization.
93 institutional holders increased their position in Adverum Biotechnologies Inc. [NASDAQ:ADVM] by around 28,469,814 shares. Additionally, 49 investors decreased positions by around 5,432,472 shares, while 13 investors held positions by with 50,878,164 shares. The mentioned changes placed institutional holdings at 84,780,450 shares, according to the latest SEC report filing. ADVM stock had 36 new institutional investments in for a total of 17,082,284 shares, while 16 institutional investors sold positions of 1,139,337 shares during the same period.